CLAIMS:

1. A liquid pharmaceutical composition comprising:

- plasminogen, or a biologically active variant thereof having at least 80% amino acid sequence identity with a native plasminogen polypeptide, in a concentration from 0.01 mg/ml ± 10% to 80 mg/ml ± 10%;

- a tonicity modifier, which is in a concentration adjusted to reach an osmolality of the composition between 180 mOsm ± 10% and 350 mOsm ± 10%, wherein the tonicity modifier is sodium chloride and is present in a concentration of between 30 mM ± 10% to 100 mM ± 10%; and

- a stabilising agent, which is arginine or glycine, in a concentration from 10 mM ± 10% to 100 mM ± 10%;

wherein the composition has a pH of 5.0 ± 10% to 8.0 ± 10%.

2. The pharmaceutical composition of claim 1, wherein the stabilising agent is arginine.

3. The pharmaceutical composition of claim 1, wherein the stabilising agent is glycine.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the pH is from 6.0 to 8.0.

5. The pharmaceutical composition of claim 4, wherein the pH is6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.0.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein the concentration of the plasminogen or biologically active variant thereof is from 5 mg/ml ± 10% to 60 mg/ml ± 10%.

7. The pharmaceutical composition of claim 6, wherein the concentration of the plasminogen or biologically active variant thereof is 40± 10%, 30± 10%, 20± 10%, 10± 10% or 5± 10% mg/ml.

8. The pharmaceutical composition of any one of claims 1 to 6, wherein the concentration of the plasminogen or biologically active variant thereof is from 2 mg/ml ± 10% to 20 mg/ml ± 10%.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the stabilising agent is in a concentration of 25 mM ± 10% to 75 mM± 10%.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein the tonicity modifier is present in a concentration of 30 mM ± 10% to 100 mM ± 10%.

11. The pharmaceutical composition of any one of claims 1 to 10, further comprising a non-reducing sugar, which is sucrose.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein said plasminogen or a biologically active variant thereof is Glu-plasminogen.

13. The pharmaceutical composition of any one of claims 1 to 12, wherein the composition contains an amount of particles equal to or greater than 10 µm that is lower than 6000 particles per container, wherein the container has a nominal content of less than or equal to 100 ml.

14. The pharmaceutical composition of claim 13, wherein the amount of particles equal to or greater than 10 µm is lower than 2000 particles per container.

15. The pharmaceutical composition of any one of claims 1 to 14, which is suitable for intravenous, subcutaneous, topical, intradermal, ophthalmic and/or intramuscular administration.

16. The pharmaceutical composition of any one of claims 1 to 18, which is a reconstituted composition.

17. The pharmaceutical composition of any one of claims 1 to 16, for use as a medicament.

18. Use of the pharmaceutical composition of any one of claims 1 to 17 for the preparation of a medicament for healing a wound, healing a tympanic membrane perforation, healing a periodontal wound, treating an infectious disease, increasing or maintaining oral health, treating posterior vitreous detachment (PVD), treating a diabetic ulcer, treating a plasminogen-deficiency, treating a thrombolysis, treating reperfusion injury to tissue, treating ischemia, treating infarction, or treating brain edema in a subject.

19. The use of claim 18, wherein the medicament is for healing a wound in a subject.

20. The use of claim 18, wherein the medicament is for treating a plasminogen-deficiency in a subject.

21. The use of claim 20, wherein the plasminogen-deficiency is type I plasminogen deficiency and wherein the pharmaceutical composition is the pharmaceutical composition of claim 12.

22. The use of claim 18, wherein the medicament is for treating a diabetic ulcer in a subject.